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Backgrounds: Of all forms of gastrointestinal malignancy, adenocarcinoma of the pancreas is 
associated with the worst survival. Management of pancreatic cancer is associated with some 
challenges. This study is aimed at determining the hospital incidence, sociodemographic 
characteristics, managements and management's outcome of carcinoma of pancreas at our 
hospital. We also discuss the management challenges encountered with these patients.  
Material and methods: We reviewed 96 pancreatic cancer patients seen at Awolowo University 
Teaching Hospital Complex, Ile –Ife, Nigeria, from July 1989 to July 2007.  
Results: There were ninety six patients diagnosed with cancer of the pancreas but only 80 
patients had histological proof of pancreatic cancer. This account for 2.1% of all malignancies 
seen and 238/100000 total admissions during the study period. The median age is 55.0. There 
were 62 (64.6%) male and 34 (35.4%) female with male to female ratio been 2:1. Duration of 
symptoms in the patients ranges from 4 weeks to 109 weeks. Only three (3.1%) patients has 
tumor located in a particular anatomical sub site: two head of pancreas and one tail of the 
pancreas. Other patients had extensive tumor involving the head and body of the pancreas. 
Two patients had pancreaticoduodenectomy, one had resection of the tumor at the tail of 
pancreas and 45 patients had triple bypass. Patients with low serum albumin and serum 
sodium and elevated transaminases at presentation, had poorer prognosis than other patients.  
Conclusion: Pancreatic cancer is not uncommon in our center with male preponderance. Most 
patients present with advanced condition only amenable to palliative measures. There are 




Pancreatic cancer is one of the most lethal human cancers and continues to be a major unsolved health 
problem at the start of the 21st century. Similarly, of all forms of gastrointestinal malignancy, 
adenocarcinoma of the pancreas is associated with the worst survival1. Most patients die within a year 
after establishment of the diagnosis2. It is the fourth leading cause of death in both men and women in 
United State of America and it has been estimated that in 2007 about 37,170 people in the United 
States will be diagnosed with pancreatic cancer and about 33,370 will die of the disease3-4.  
 
The peak incidence of pancreatic carcinoma occurs in the seventh decade with a slight male to female 
predominance 5. There are variations in incidence in different populations ranging from 2.2 new cases 
per 100,000 population in India, Kuwait, and Singapore to 12.5/100,000 in Sweden 5, 6. The incidence 
in most developed countries is similar to that of the United States6. 
 
Most research on pancreatic cancer has come from developed countries. Some of these researches 
have indicted some environmental factors in the occurrence of this disease7-8. The environmental 
factors include cigarette smoking, alcohol consumption, high meat intake and occupational exposure 
to carcinogen like DDT and other organochlorine pesticides. Most of these environmental factors are 
very prevalent in Africa especially Nigeria- the world largest black nation. Study from Egypt showed 
that the incidence of pancreatic cancer is higher in the area of the country where this environmental 
factor abound 9-10. However, few works have been done on this area of interest in Nigeria. The need to 
look at local data also becomes very imperative because of the finding of some study that African 
American and economic disadvantage population have higher incidence of pancreatic cancer 3-7. 
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This retrospective study was aimed at highlighting the hospital incidence, sociodemographic 
characteristics, managements and management's outcome of carcinoma of pancreas at Obafemi 
Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria. We also discuss the challenges 
associated with management of the disease in resource-scarce settings that are typical of the health 
sector in the sub-Saharan African region.  
Patients and Methods 
 
The study was conducted at Obafemi Awolowo University Teaching Hospital Complex, Ile –Ife, 
Nigeria, from July 1989 to June 2007. The hospital services the rural and semi-urban agrarian 
communities in the southwestern Nigeria. The hospital serves as the referral tertiary hospital for an 
estimated population of approximately 7.7 million persons in the southwestern states of Nigeria. 
Data Collection. 
 
This was a retrospective cohort study. Admission and discharge diagnosis and procedure codes as 
well as the cancer registry database were obtained from the Corporate Data Store of the hospital. 
Current procedural terminology (CPT) and International Classification of Diseases Ten Revision 
(ICD-10) codes for “Triple bypass”, “pancreaticoduodenectomy” and “pancreatic cancer” were used 
to identify patients with proven or suspected pancreas neoplasm undergoing surgery. Manual review 
of patient records was performed to obtain relevant data points. The Institutional Ethical Committee 
approved the study. The data collected include the sociodemographic, laboratory parameters and the 
treatment modalities, as well as, the outcome of management. 
 
The diagnosis of pancreatic cancer was made using the combination of clinical parameters, upper 
gastrointestinal endoscopy and radiological findings. Clinical parameters used included jaundice, 
upper abdominal mass, upper abdominal pain that radiate to the back, weight loss and palpable gall 
bladder. Radiological parameters included ultrasound and/or Computerized tomography scan showing 
pancreatic mass. Upper gastrointestinal endoscopy was done for most of the patients to rule out the 
possibility of gastric cancer. Endoscopic retrograde cholangiopancreatography was not done for any 
of the patients because the facility was not available. All the patients with conflicting findings which 
could not be substantiated at surgery were excluded from the study. Histolopathological finding 
further corroborated the diagnoses for patients that had surgery or on postmortem examination. 
Sixteen (16.7%) patients do not have histopathology result.  
  
All the data obtained were coded, edited appropriately and entered into personal computer. Analysis 
of the data was done using Statistical Packaging for Social Sciences (SPSS) version 11.0. Simple 
descriptive statistics were used. Median and frequencies were calculated based on the numerous data 
points. The P values were provided to indicate statistical significance. P value less than 0.05 were 
regarded as significant. Chi-square tests were used to compare categorical variables such as sex. 




There were ninety six patients diagnosed with cancer of the pancreas but only 80 patients had 
histological proof of pancreatic cancer. This account for 2.1% of all malignancies seen and 
238/100000 total admissions during the study period. The age of the patients ranges from 32 to 90 
years. The median of the age is 55.0. As shown in figure 1, the most common age group affected with 
pancreatic cancer is age group 51-60. There were 62 (64.6%) male and 34 (35.4%) female with male 
to female ratio been 2:1. Majority of the patients were farmers (39.8%) and traders (26.4%). Other 
patients were either artisan or work in Government establishment.  
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Duration of symptoms ranged from 4 weeks to 109 weeks with a median of 8 weeks. None of our 
patients have family history of pancreatic cancer. Only eleven (11.5%) have previous history of 
diabetic mellitus (DM) before the onset of the symptoms. The diagnosis of DM was made within one 
year prior to the commencement of the symptoms in 8 of the 11 patients. Seven and ten patients had 
significant history of cigarette smoking and alcohol intake respectively.  On investigation, 98% of the 
patients had elevation of alkaline phosphatase, 20% had elevated Aspatate transaminate, 98% had 
elevated bilirubin and 62.5% had packed cell volume of less than 25 at presentation. 
 
Only 3 (3.1%) patients has tumor located in a specified anatomical sub site: 2 in head of pancreas and 
one in tail of the pancreas. Other patients had extensive tumor involving the head and body of the 
pancreas. There were liver metastases in 20(20.8%) patients at presentation.   
 
Table 1. Factors Affecting the Outcome of Managements of Patients with Pancreatic Cancer. 
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Figure 1: Distribution of age of 
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Table 2. Complication Associated with Methods of Triple Bypass 
 
Complications Braun Method Roux-en-Y method 
 
Bile leak 











Total 9 2 
 
Fifty five (57.3%) patients had surgery. Two patients with localized tumor of the head had 
pancreaticoduodenectomy. A patient with tumor at the pancreatic tail had resection of the tumor and 
splenectomy. Forty-five (81.8%) of the operated patients had locally advanced pancreatic mass. These 
patients had triple bypass to relieve the obstructive jaundice. Eleven of the 45 triple bypasses were 
done with isolated bowel segment (Roux-en-Y) while in the others bowel loops were used (Braun).  
Seven patients had biopsy alone of the pancreatic mass or the lymph node because of the widespread 
metastasis to the bowel, liver and other organ in the peritoneal cavity. Fourteen patients had adjuvant 
chemotherapy. Agents used include 5-fluorouracil and Adramycin. 
 
One of the patients that had pancreaticoduodenectomy presented three month later with metastasis to 
the spine. He died five month after surgery. The other patient who had pancreaticoduodenectomy was 
lost to follow-up after a year. No recurrence was recorded for the patient with tumor at the tail of 
pancreas after 5 years of follow up. Median survival for patients that had triple bypass using a bowel 
loop was 3 months, while the median survival for patients that had triple bypass using an isolated 
bowel segment was 5 months.  This was statistically significant (p=0.02). One of the patients that had 
pancreaticoduodenectomy had bile leak which was managed conservatively. Within one month of 
presentation, 46 (47.9%) patients with pancreatic cancer died. As shown in table 1, the factors that 
were found to be significant in patients that died within one month of presentation include elevated 
transaminases, low sodium, serum protein and bicarbonate. Table 2 shows the various complications 
from bypass surgery. The most common complication of triple bypass is bile leak which was seen in 4 
patients.  
Discussion 
Despite past efforts, conventional treatment approaches, such as surgery, radiation, chemotherapy, or 
combinations of these, have had little impact on the course of pancreatic cancer. The tumor is rarely 
curable2,3. In this study, we found that the hospital incidence of pancreatic cancer is 238 per 100, 000 
hospital admission. It also accounts for 2.1% of cancer cases seen in our centre. For several decades, 
the incidence of pancreatic cancer has been consistently higher in blacks than in whites in the United 
States8.11-12. From 1995 to 1999, the average annual age-adjusted incidence rates were 16.6/100,000 
for blacks and 10.7/100,000 for whites12. The incidence of pancreatic cancer is higher in black 
patients owing to several factors attributable to genetic mutations, socioeconomic status, smoking, 
long-term diabetes, and alcohol use 11-12. However in our series, aside from the fact that most of our 
patients belong to low socioeconomic class, few of our patients have history suggestive of these 
identified risk factors. Majority of our patients are farmers. Occupational exposure to carcinogen may 
play a major role in the occurrence of pancreatic cancer in our environment as stated in previous work 
from Africa 9-10. Further studies will be necessary to identify the particular carcinogen that our patients 
are exposed to. One interesting finding of this study is that the peak age of occurrence of pancreatic 
cancer is 6th decade. Generally, cancers tend to occur in earlier age in the country; and pancreatic 
cancer is not an exception13. Our study concurred with finding in other studies that showed male 
preponderance in pancreatic cancer6,13-14. 
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Pancreatic cancer can mimic other benign conditions like chronic pancreatitis and biliary tree stone. 
Several modalities are used in developed centres before primary therapy is initiated. These modalities 
include endoscopic retrograde cholangiopancreatography, laparoscopy, endoscopic ultrasound, helical 
computerized tomography (CT), Magnetic resonance imaging and the use of tumor markers 7,15-16. 
Most of these facilities are not readily available in most centers in the developing countries. Though 
CT scan is available, the cost of the procedure is prohibitive to most of our patients who are poor. 
This suggests an urgent need for formal social support structure in our environment. Most developing 
centers like ours depend on clinical presentations and few radiological investigations while 
confirmation of the diagnosis is done at laparotomy or at autopsy.  Previous study has shown that 
pancreatic cancer is the most common cause of obstructive jaundice in our environment13. Hence, all 
patients with features of obstructive jaundice are painstakingly screened for pancreatic cancer and 
subsequently, offered surgery after stabilization. The need to undertake definitive treatment without 
prior tissue diagnosis had been substantiated by previous study16-17. 
 
At presentation, most of our patients had advanced disease. Resection rate is about 3% which was 
very low compared with data from developed country where resection rate of as high as 15-20% has 
been quoted7. Stage of the tumor has been found to be an important predictor of resectability and 
death in patients with pancreatic tumor18. Because of the location of pancreas, early symptoms of 
pancreatic cancer are so vague and are usually ignored by most patient. Presentation with advanced 
stage of the disease may also be due to poor health seeking behaviour of our patients 19-20. Obviously, 
a high index of suspicion on the part of health workers is essential to early detection of pancreatic 
cancer. Another reason for late presentation in our patients may be due to aggressive growth 
behaviour of the pancreatic cancer which lead to early dissemination of the tumor7,21. Various efforts 
had been made on how to diagnose pancreatic cancer early with little success16,22. Presently, no 
population screening modality is available for pancreatic cancer. Moreover, targeted screening is also 
very difficult for pancreatic cancer because primary causal factors for this tumor are poorly 
understood. While effort is been made along this line, it is worthy to note that endoscopic 
ultrasonography has been shown to be a reliable way to detect tumor invasion of visceral vessels and 
thus predict unresectability and it also has the potential to be used to diagnose pancreatic cancer 
early22-23. 
 
Most of our patients had diversion of bile and the gastric contents to ameliorate the jaundice and the 
possible gastric outlet obstruction. We found that patients that had triple bypass using Roux –en- Y 
live longer than when a loop of bowel was used for the bypass. A randomized control trial will be 
needed to substantiate this finding. However, a diversion using Roux en Y is said to be associated 
with less complication21. There are debates about the rational for triple bypass since the procedure is 
essentially palliative21-22. The rate of gastric outlet obstruction is said to be about 20% and the rate 
may be on the increase the longer the patient live3,23. Most of our patients are poor and may not be 
able to afford a repeat surgery hence the need to do a more encompassing surgery like triple bypass 
when indicated. Endoscopy bypass was not done for any of our patient because the facility was not 
available. These may not be a disadvantage because it has been found that surgical bypass are more 
durable than endoscopic stents which is prone to recurrent obstruction and cholangitis24 .It worth 
noting however, that the minimally invasive approach is associated with considerable less initial 
morbidity and mortality than surgical bypass24-26. 
 
The need for adjuvant therapy in pancreatic cancer cannot be over emphasized. Even with complete 
surgical resection, most patients will die of recurrent disease because of the multifocality of the 
disease and micrometastasis27-29. Several studies had shown that outcome of patients are improved 
when placed on adjuvant chemotherapy, radiotherapy or combination of both7,28-29. Pancreatic cancer 
is moderately sensitive to few agents like gemcitabine, capecitabine, cisplatin, bevacizumab and 
cetuximab8,30. Most of these agents are more toxic, rarely available in our environment or very 
expensive. One important question that is yet to find an answer is the reason why pancreatic cancer is 
resistance to most commonly available chemotherapy. Radiotherapy facilities are extremely 
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congested; hence, the facilities are made available to those that will benefit most from the facilities 
and the privileged few. These made management of patients with pancreatic cancer very difficult. 
 
We found that patients with elevated transaminases, low serum sodium and reduced total protein 
indicate that patients had very advanced disease with a much reduced life expectancy. These may be 
due to involvement of the liver in this condition. These simple parameters can help predict a poorer 
outcome at presentation. Further study will be needed to substantiate this finding. For long time, 
pancreatic cancer has been regarded as terminal disease; hence little attention is given to the research 
on the disease. Report on pancreatic cancer is extremely scarce in Nigeria or Africa. If it is true that 
blacks have higher risk to develop pancreatic cancer, concerted effort must be put to characterize 
pancreatic cancer in Nigeria, the largest black nation in the world. 
 
Conclusion 
 Pancreatic cancer is not uncommon in our center with a male preponderance.  
 Most patients present with advanced condition only amenable to palliative measures.  
 There are significant challenges in the area of diagnosis, screening, treatment and research. 
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